Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2014 1
2017 1
2018 1
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer.
Aokage K, Tsuboi M, Zenke Y, Horinouchi H, Nakamura N, Ishikura S, Nishikawa H, Kumagai S, Koyama S, Kanato K, Kataoka T, Wakabayashi M, Fukutani M, Fukuda H, Ohe Y, Watanabe SI; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. Aokage K, et al. Jpn J Clin Oncol. 2022 Apr 6;52(4):383-387. doi: 10.1093/jjco/hyab208. Jpn J Clin Oncol. 2022. PMID: 34999817 Free PMC article.
BACKGROUND: Superior sulcus tumours (SSTs) are relatively uncommon and one of the most intractable lung cancers among non-small cell lung cancer (NSCLC). We planned a multicenter, single-arm confirmatory trial of new multidisciplinary treatment using immune-checkpoi …
BACKGROUND: Superior sulcus tumours (SSTs) are relatively uncommon and one of the most intractable lung cancers among non-small cell …
Prospective, Multi-Institutional Observational Study of Deterioration in Activities of Daily Living in Elderly Patients After Lung Cancer Surgery.
Takei H, Kunitoh H, Wakabayashi M, Kataoka T, Sekino Y, Mizutani T, Tsuboi M, Ikeda N, Asamura H, Okada M, Takahama M, Ohde Y, Okami J, Shiono S, Aokage K, Watanabe SI; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group, Japan. Takei H, et al. JTO Clin Res Rep. 2023 Jul 17;4(8):100550. doi: 10.1016/j.jtocrr.2023.100550. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37600227 Free PMC article.
A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thin-section computed tomography (JCOG1211).
Aokage K, Saji H, Suzuki K, Mizutani T, Katayama H, Shibata T, Watanabe S, Asamura H; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. Aokage K, et al. Gen Thorac Cardiovasc Surg. 2017 May;65(5):267-272. doi: 10.1007/s11748-016-0741-1. Epub 2017 Mar 2. Gen Thorac Cardiovasc Surg. 2017. PMID: 28255781 Clinical Trial.
INTRODUCTION: Lobectomy has been the standard surgery for even stage I lung cancer since the validity of limited resection for stage I lung cancer was denied by the randomized study reported in 1995. ...CONCLUSION: This study is one of the pivotal trial of lung …
INTRODUCTION: Lobectomy has been the standard surgery for even stage I lung cancer since the validity of limited resection for stage …
A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413).
Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T, Wakabayashi M, Shibata T, Okada M; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG-LCSSG). Hishida T, et al. Jpn J Clin Oncol. 2018 Feb 1;48(2):190-194. doi: 10.1093/jjco/hyx170. Jpn J Clin Oncol. 2018. PMID: 29177507 Clinical Trial.
In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to confirm the clinical benefit of lobe-specific nodal dissection for clinical Stage I-II non-small cell lung cancer. ...This study is t …
In January 2017, the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group commenced a randomized Phase III trial to …
A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, Watanabe S, Yamamoto N, Tamura T, Asamura H; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group; Lung Cancer Study Group of the Japan Clinical Oncology Group. Eba J, et al. Jpn J Clin Oncol. 2014 Apr;44(4):379-82. doi: 10.1093/jjco/hyt233. Epub 2014 Jan 27. Jpn J Clin Oncol. 2014. PMID: 24474818 Clinical Trial.
Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm …
Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuro …
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, Kato H; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. Nagai K, et al. J Thorac Cardiovasc Surg. 2003 Feb;125(2):254-60. doi: 10.1067/mtc.2003.15. J Thorac Cardiovasc Surg. 2003. PMID: 12579093 Free article. Clinical Trial.
OBJECTIVE: We performed a prospective randomized trial in patients with potentially resectable stage IIIA N2 non-small cell lung cancer to confirm the efficacy of induction chemotherapy before surgical resection. ...CONCLUSION: This randomized trial to compare induction ch …
OBJECTIVE: We performed a prospective randomized trial in patients with potentially resectable stage IIIA N2 non-small cell lung canc …